Patrys Ltd (PAB)

Sydney
Currency in AUD
Disclaimer
0.011
0.000
(0.00%)
Delayed Data
Day's Range
0.011
0.012
52 wk Range
0.010
0.034
Volume
53,478
Bid/Ask
0.011 / 0.012
Prev. Close
0.011
Open
0.012
Day's Range
0.011-0.012
52 wk Range
0.01-0.034
Volume
53,478
Average Volume (3m)
3,174,261
1-Year Change
-42.86%
Shares Outstanding
2,057,268,394
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

Patrys Ltd News

Patrys Ltd Analysis

Patrys Ltd Company Profile

Patrys Limited is an Australia-based company. The Company focuses on the development of antibody therapies for the treatment of cancer. It is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. It also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The Company is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.